Pfizer will merge off-patent drug unit with EpiPen maker Mylan in restructuring
Pfizer agreed Monday to combine its off-patent drugs division, which controls treatments like the statin Lipitor, with the pharmaceutical company ... Read more
Pfizer agreed Monday to combine its off-patent drugs division, which controls treatments like the statin Lipitor, with the pharmaceutical company ... Read more